After hours: 4:08PM EDT
|Bid||9.55 x 1000|
|Ask||10.10 x 1400|
|Day's Range||9.93 - 10.33|
|52 Week Range||9.93 - 26.10|
|Beta (3Y Monthly)||0.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.17|
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is a small-cap stock with a market capitalization of US$349m. While investors...
WALTHAM, Mass., May 17, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it will host an Analyst Day for the investment community on Wednesday, May 22,.
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
President & CEO of Amag Pharmaceuticals Inc (NASDAQ:AMAG) William K Heiden bought 10,000 shares of AMAG on 05/09/2019 at an average price of $10.7 a share.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) BioSig Technologies ...
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -503.64% and -16.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Waltham, Massachusetts-based company said it had a loss of $3.54 per share. Losses, adjusted for restructuring costs, were $3.32 per share. The specialty drugmaker posted revenue of $75.8 million in ...
Achieved record Feraheme revenue growth and more than 50% market share for Makena auto-injector Completed integration of Perosphere Pharmaceuticals Inc. and progressed.
AMAG Pharmaceuticals, Inc. (AMAG) announced today that it will present new data related to investigational drug bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) and Feraheme® (ferumoxytol) related to iron deficiency anemia (IDA) resulting from abnormal uterine bleeding (AUB) at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting taking place in Nashville, Tennessee from May 3-5.
WALTHAM, Mass., April 30, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its first quarter 2019 financial results will be released on Tuesday, May 7,.
AMAG Pharmaceuticals, Inc. (AMAG) today announced that the Board of Directors of AMAG approved inducement awards to a new employee of (i) an option to purchase 15,000 shares of common stock and (ii) 7,500 restricted stock units. The option will have an exercise price equal to the closing price of AMAG’s common stock on the grant date and will be exercisable in four equal annual installments beginning on the first anniversary of April 29, 2019 (the grant date). The restricted stock units will vest in three equal annual installments beginning on the first anniversary of the grant date and will be subject to the restricted stock unit agreement pursuant to which the restricted stock units will be granted.
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMAG Pharmaceuticals, Inc. (AMAG) today announced the appointment of Nancy Griffith, Ph.D., as vice president, scientific communications and medical operations, reporting to Brian Robinson, M.D., senior vice president, medical affairs. Dr. Griffith will be responsible for the creation and implementation of AMAG’s medical communications and publication strategies.
The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the last three years have been particularly tough on longer term AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shareholders. So t...
“We are pleased to welcome Dr. Phillips and Ms. O’Brien to AMAG’s board,” said Gino Santini, chairman of the board of AMAG. “As AMAG continues to invest and focus on the development and commercialization of novel pharmaceutical products that address unmet medical needs, the deep experience and expertise that Dr. Phillips and Ms. O’Brien each bring will be invaluable to AMAG.
WALTHAM, Mass., April 02, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Ted Myles, chief financial officer, will present at the Needham 18th Annual.
March of Dimes and AMAG Pharmaceuticals, Inc. (AMAG) today announced Baystate Medical Center’s Wesson Women’s Clinic in Springfield, Mass. as the first Supportive Pregnancy Care (SPC) site, supported by AMAG to help improve mom and baby health during pregnancy, labor and delivery, and infancy.
For more than a decade, the recommended treatment for most pregnant women who previously had given birth prematurely was a weekly injection of a synthetic progestin hormone. On March 8, the company said a long-term clinical trial revealed no difference in the preterm birth rates of 1,700 pregnant women who took either their treatment, named Makena, or a placebo. Most experts and medical groups say it’s too early to make a call on Makena.
Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.